File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2147/IJN.S28783
- Scopus: eid_2-s2.0-84862335613
- PMID: 22359452
- WOS: WOS:000302715500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.
Title | Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. |
---|---|
Authors | |
Keywords | Camptothecin Cancer Gold porphyrin Lipid nanoparticles Neuroblastoma |
Issue Date | 2012 |
Publisher | Dove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?journal_id=5 |
Citation | International Journal Of Nanomedicine, 2012, v. 7, p. 731-737 How to Cite? |
Abstract | Development of anticancer drugs is challenging. Indeed, much research effort has been spent in the development of new drugs to improve clinical outcomes with minimal toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles as a carrier platform. We encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and compared using an in vivo neuroblastoma (N2A) model. We showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of drug delivery into tumor tissue and subsequently more effective antitumor activity. This specific design of a chemotherapeutic agent using nanotechnology is important in the development of a safe and effective drug in cancer therapy. |
Persistent Identifier | http://hdl.handle.net/10722/146855 |
ISSN | 2023 Impact Factor: 6.6 2023 SCImago Journal Rankings: 1.273 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, P | en_HK |
dc.contributor.author | Zhang, R | en_HK |
dc.contributor.author | Li, V | en_HK |
dc.contributor.author | Liu, X | en_HK |
dc.contributor.author | Sun, RWY | en_HK |
dc.contributor.author | Che, CM | en_HK |
dc.contributor.author | Wong, KKY | en_HK |
dc.date.accessioned | 2012-05-23T05:42:46Z | - |
dc.date.available | 2012-05-23T05:42:46Z | - |
dc.date.issued | 2012 | en_HK |
dc.identifier.citation | International Journal Of Nanomedicine, 2012, v. 7, p. 731-737 | en_HK |
dc.identifier.issn | 1178-2013 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/146855 | - |
dc.description.abstract | Development of anticancer drugs is challenging. Indeed, much research effort has been spent in the development of new drugs to improve clinical outcomes with minimal toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles as a carrier platform. We encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and compared using an in vivo neuroblastoma (N2A) model. We showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of drug delivery into tumor tissue and subsequently more effective antitumor activity. This specific design of a chemotherapeutic agent using nanotechnology is important in the development of a safe and effective drug in cancer therapy. | en_HK |
dc.language | eng | en_US |
dc.publisher | Dove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?journal_id=5 | - |
dc.relation.ispartof | International journal of nanomedicine | en_HK |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Camptothecin | - |
dc.subject | Cancer | - |
dc.subject | Gold porphyrin | - |
dc.subject | Lipid nanoparticles | - |
dc.subject | Neuroblastoma | - |
dc.title | Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Wong, KK: kkywong@hkucc.hku.hk | en_HK |
dc.identifier.authority | Wong, KK=rp01392 | en_HK |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.2147/IJN.S28783 | - |
dc.identifier.pmid | 22359452 | - |
dc.identifier.pmcid | PMC3282612 | - |
dc.identifier.scopus | eid_2-s2.0-84862335613 | en_HK |
dc.identifier.hkuros | 199742 | en_US |
dc.identifier.volume | 7 | en_HK |
dc.identifier.spage | 731 | en_HK |
dc.identifier.epage | 737 | en_HK |
dc.identifier.isi | WOS:000302715500001 | - |
dc.publisher.place | New Zealand | - |
dc.identifier.scopusauthorid | Lee, P=8212119000 | en_HK |
dc.identifier.scopusauthorid | Zhang, R=45261666800 | en_HK |
dc.identifier.scopusauthorid | Li, V=55253800500 | en_HK |
dc.identifier.scopusauthorid | Liu, X=37461750900 | en_HK |
dc.identifier.scopusauthorid | Sun, RW=55253605200 | en_HK |
dc.identifier.scopusauthorid | Che, CM=55253537600 | en_HK |
dc.identifier.scopusauthorid | Wong, KK=24438686400 | en_HK |
dc.identifier.issnl | 1176-9114 | - |